首页 > 科研队伍 > 临床客座

王延江

王延江,1971年4月出生,现任第三军医大学大坪医院神经内科主任,主任医师、教授。担任中华医学会神经病学分会常委、Neuroscience Bulletin杂志associate editor、中华神经科杂志编委。获得国家杰出青年科学基金、国家自然科学基金重点项目、国家自然科学基金重大研究计划重点项目、国家自然科学基金创新研究群体等课题资助。获得Journal of Alzheimers Disease杂志2019年度Alzheimer Award。

    主要研究方向及内容

    1.从系统角度探讨阿尔茨海默病的发生机制和防治策略
    2.阿尔茨海默病的外周生物标志物研究
    3.血管性认知障碍的发生机制和防治

    代表性论文

    Sun HL, Chen SH, Yu ZY, Cheng Y, Tian DY, Fan DY, He CY, Wang J, Sun PY, Chen Y, Tan CY, Wang JP, Song W, Zhou HD, Chen XW, Hu ZA, Bu XL*, Wang YJ*. Blood cell-produced amyloid-β induces cerebral Alzheimer-type pathologies and behavioral deficits. Mol Psychiatry. 2020 in press.


    Wang J, Jin WS, Bu XL, Zeng F, Huang ZL, Li WW, Shen LL, Zhuang ZQ, Fang Y,Sun BL, Zhu J, Yao XQ, Zeng GH, Dong ZF, Yu JT, Hu Z, Song W, Zhou HD, Jiang JX, Liu YH*, Wang YJ*. Physiological clearance of tau in the periphery and its therapeutic potential for tauopathies. Acta Neuropathol. 2018;136(4):525-536. (Commented by Nature Reviews Neurology)


    Shen LL, Ma?ucat-Tan NB, Gao SH, Li WW, Zeng F, Zhu C, Wang J, Bu XL, Liu YH, Gao CY, Xu ZQ, Bobrovskaya L, Lei P, Yu JT, Song W, Zhou HD, Yao XQ, Zhou XF*, Wang YJ*. The ProNGF/p75NTR pathway induces tau pathology and is a therapeutic target for FTLD-tau. Mol Psychiatry. 2018;23(8):1813-1824.


    Jin WS, Shen LL, Bu XL, Zhang WW, Chen SH, Huang ZL, Xiong JX, Gao CY, Dong Z,He YN, Hu ZA, Zhou HD, Song W, Zhou XF, Wang YZ, Wang YJ*. Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model. Acta Neuropathol. 2017;134(2):207-220. (Highlighted by Nature Reviews Neurology)


    Wang J, Gu B, Masters CL*, Wang YJ*. A systemic view of Alzheimer’s disease: insights from amyloid-beta metabolism beyond the brain. Nat Rev Neurol 2017; 13(10):612-623.


    Bu XL, Xiang Y, Jin WS, Wang J, Shen LL, Huang ZL, Zhang K, Liu YH, Zeng F, Liu JH, Sun HL, Zhuang ZQ, Chen SH, Yao XQ, Giunta B, Shan YC, Tan J, Chen XW, Dong ZF, Zhou HD, Zhou XF, Song W*, Wang YJ*. Blood-derived amyloid-β protein induces Alzheimer’s disease pathologies. Mol Psychiatry. 2018; 23(9):1948-1956.


    Yao XQ, Jiao SS, Saadipour K, Zeng F, Wang QH, Zhu C, Shen LL,Zeng GH, Liang CR, Wang J,Liu YH, Hou HT, Xu X, Su YP,Fan XT, Xiao HL, Lue LF,Zeng YQ, Giunta B, Zhong JH,Walker DG, Zhou HD,Tan J, Zhou XF*, Wang YJ*. p75NTR ectodomain is a physiological neuroprotective molecule against amyloid-beta toxicity in the brain of Alzheimer’s disease. Mol Psychiatry. 2015; 20(11):1301-1310.


    Xiang Y, Bu XL, Liu YH, Zhu C, Shen LL, Jiao SS, Zhu XY, Giunta B, Tan J, Song W, Zhou HD, Zhou XF, Wang YJ*. Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer’s disease. Acta Neuropathologica. 2015;130(4):487-499.


    Jiao SS, Yao XQ, Liu YH, Wang QH, Zeng F, Lu JJ, Liu J, Zhu C, Shen LL, Liu CH, Wang YR, Zeng GH, Parikh A., Chen J, Liang CR, Xiang Y, Bu XL, Deng J, Li J, Xu J, Zeng YQ, Xu X, Xu HW, Zhong JH, Zhou HD, Zhou XF*, Wang YJ*. Edaravone alleviates Alzheimer’s disease-type pathologies and cognitive deficits. Proc Natl Acad Sci U S A. 2015; 112(16):5225-5230.


    Wang YJ. Alzheimer disease:Lessons from immunotherapy for Alzheimer disease. Nat Rev Neurol. 2014;10(4):188-189.


    Liu YH, Giunta B, Zhou HD, Tan J, Wang YJ*. Immunotherapy for Alzheimer disease: the challenge of adverse effects. Nat Rev Neurol. 2012;8(8):465-469.